MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-369-7100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.62 million
Profitability
Miscellaneous
Employees32
Next Earnings Date8/28/2019 (Confirmed)
OptionableOptionable
MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma Inc (NASDAQ:MEIP) issued its earnings results on Thursday, February, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.01. The company earned $2.05 million during the quarter, compared to analysts' expectations of $3.05 million. MEI Pharma had a negative net margin of 1,443.85% and a negative return on equity of 88.85%. View MEI Pharma's Earnings History.
When is MEI Pharma's next earnings date?
What price target have analysts set for MEIP?
3 equities research analysts have issued twelve-month target prices for MEI Pharma's shares. Their predictions range from $10.00 to $10.00. On average, they anticipate MEI Pharma's share price to reach $10.00 in the next year. This suggests a possible upside of 562.3% from the stock's current price. View Analyst Price Targets for MEI Pharma.
What is the consensus analysts' recommendation for MEI Pharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.
What are Wall Street analysts saying about MEI Pharma stock?
Here are some recent quotes from research analysts about MEI Pharma stock:
- 1. HC Wainwright analysts commented, "$10 PT ICML data update points to expanded opportunity in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). On the heels of reporting promising data in follicular lymphoma (FL) at ASCO earlier this month, MEI Pharma presented more color on its ongoing Phase 1b study in B-cell lymphomas in an oral presentation at ICML. Herein, we highlight the newly reported 100% objective response rates (ORR) with favorable safety in CLL/ SLL, which we believe may bring PI3K inhibition back in the game in the highly competitive CLL/SLL landscape (discussed below)." (6/24/2019)
- 2. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (5/1/2019)
Has MEI Pharma been receiving favorable news coverage?
Headlines about MEIP stock have trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MEI Pharma earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for MEI Pharma.
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include Aptorum Group (APM), Milestone Pharmaceuticals (MIST), Sinovac Biotech (SVA), Syros Pharmaceuticals (SYRS), Dova Pharmaceuticals (DOVA), Urogen Pharma (URGN), Puma Biotechnology (PBYI), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Evolus (EOLS), Organogenesis (ORGO), Flexion Therapeutics (FLXN), BioSpecifics Technologies (BSTC), Obseva (OBSV) and CytomX Therapeutics (CTMX).
What other stocks do shareholders of MEI Pharma own?
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Dr. Daniel P. Gold, CEO, Pres & Director (Age 65)
- Mr. Brian G. Drazba CPA, Sec. & CFO (Age 58)
- Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 55)
- Dr. Robert D. Mass M.D., Chief Medical Officer (Age 65)
- Mr. David A. Walsey, VP of IR & Corp. Communications
Who are MEI Pharma's major shareholders?
MEI Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (7.97%), BlackRock Inc. (5.12%), Vanguard Group Inc. (4.00%), Renaissance Technologies LLC (3.60%), Sio Capital Management LLC (2.12%) and Wasatch Advisors Inc. (1.80%). Company insiders that own MEI Pharma stock include Charles V Baltic III and David M Urso. View Institutional Ownership Trends for MEI Pharma.
Which institutional investors are selling MEI Pharma stock?
MEIP stock was sold by a variety of institutional investors in the last quarter, including Sio Capital Management LLC, Indus Capital Partners LLC, Vivo Capital LLC, Morgan Stanley, Connor Clark & Lunn Investment Management Ltd. and Wells Fargo & Company MN. View Insider Buying and Selling for MEI Pharma.
Which institutional investors are buying MEI Pharma stock?
MEIP stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., Wasatch Advisors Inc., Bank of New York Mellon Corp, Jane Street Group LLC, Charles Schwab Investment Management Inc. and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for MEI Pharma.
How do I buy shares of MEI Pharma?
Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
One share of MEIP stock can currently be purchased for approximately $1.51.
How big of a company is MEI Pharma?
MEI Pharma has a market capitalization of $107.65 million and generates $1.62 million in revenue each year. The company earns $-40,060,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.
What is MEI Pharma's official website?
How can I contact MEI Pharma?
MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]
MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
